STAT
FEBRUARY 8, 2024
Despite widespread promises of reform after the murder of George Floyd in 2020, in 2023, police killed at least 1,246 people — the most in more than a decade. This police violence is intertwined with a parallel public policy disaster: America’s abysmal mental health systems that force police officers to function as de facto mental health workers.
Fierce Pharma
FEBRUARY 8, 2024
Thursday, when senators questioned three Big Pharma CEOs about the high price of drugs in the U.S., Health, Education, Labor and Pensions (HELP) committee chairman Bernie Sanders, I-Vermont, put th | CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 8, 2024
A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying, jeopardizing timely decision-making on how vaccines should be used in this country. The Advisory Committee on Immunization Practices, which has in recent years been a 15-person panel, has eight vacancies — one of which dates back more than a year.
Drug Topics
FEBRUARY 8, 2024
The link between high-risk human papillomavirus infection and atherosclerotic cardiovascular disease mortality was strongest in women with obesity.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 8, 2024
A medical journal has retracted two studies claiming to show the harms of the abortion pill mifepristone, citing conflicts of interest by the authors and flaws in their research. Two of the three studies retracted by medical publisher Sage Perspectives were cited in a pivotal Texas court ruling that has threatened access to the pill. The U.S.
Pharmacy Times
FEBRUARY 8, 2024
This agent can prevent the depletion of heparan sulphate in the endothelial glycocalyx layer of endothelial cells, ultimately protecting against vision loss and renal failure caused by diabetes.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
FEBRUARY 8, 2024
With $45.8 billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. | AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014. But questions have emerged for one of the company's key growth drivers.
STAT
FEBRUARY 8, 2024
People receiving a double dose of naloxone are no more likely to survive an opioid overdose than people receiving a standard, 4-milligram nasal spray, according to a new study. The new paper , published Thursday in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, showed no significant difference in survival rates between people who were revived using 4- and 8-milligram sprays of naloxone, commonly known by the brand name Narcan.
Pharmacy Times
FEBRUARY 8, 2024
Ibrutinib and other Bruton tyrosine kinase inhibitors can cause the development of or worsen pre-existing hypertension.
STAT
FEBRUARY 8, 2024
The world may be getting over the idea that men are from Mars and women from Venus , but public perception still holds that testosterone is the male hormone , and estrogen, the female. That can make the following fact a little puzzling: There is more testosterone than estrogen in a premenopausal woman’s body. Testosterone levels decrease with time and reach especially low values after menopause, which can lead to loss of bone density, lower energy, and depression.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
FEBRUARY 8, 2024
Investigators found high incidences of non-susceptibility with penicillin and increasing resistance to macrolides for pneumococcal diseases.
STAT
FEBRUARY 8, 2024
LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly. Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals.
pharmaphorum
FEBRUARY 8, 2024
Explore the commercial research landscape in the UK and the evolution of the National Institute for Health Research (NIHR) through an informative webinar.
STAT
FEBRUARY 8, 2024
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. A looming test for neoantigen cancer vaccines Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that i
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
FEBRUARY 8, 2024
Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.
STAT
FEBRUARY 8, 2024
Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials.
Pharmacy Times
FEBRUARY 8, 2024
The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.
STAT
FEBRUARY 8, 2024
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck CEO Robert Davis, Johnson and Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared.
Fierce Healthcare
FEBRUARY 8, 2024
Enrollment in individual market plans continues to grow, with a record high of 21.3 million people signing up for plans during the most recent open enrollment period. | CEO Mark Bertolini told investors that Oscar “closed out 2023 with another strong quarter, driving financial performance for the full year.
pharmaphorum
FEBRUARY 8, 2024
Stay up to date with the latest updates in the world of clinical trials. This week's highlights include Bayer's new study on aflibercept, BioNTech's groundbreaking research, and the exciting developments from Duality Bio. Get all the important information here.
Fierce Pharma
FEBRUARY 8, 2024
Roughly an eon ago in the pharma industry (read: 20 years), Sandoz carved out a sizable generics foothold through dual mergers with Germany’s Hexal and U.S.-based Eon Labs. | Nearly 20 years after Sandoz carved out a sizable generics foothold via dual mergers with Germany’s Hexal and U.S.-based Eon Labs, the Swiss manufacturing giant is mothballing one of the latter company’s main manufacturing sites.
Hospital Pharmacy Europe
FEBRUARY 8, 2024
Tiene Bauters, PharmD PhD, Pharmacy Department , Ghent University Hospital in Belgium, offers her take on what’s hot on the horizon for hospital pharmacy in 2024. We have just stepped into a new year, and it is already clear that the pharmacy landscape is set to experience significant innovations and challenges over the coming weeks and months. These will undoubtedly present great opportunities for hospital pharmacists and their teams.
pharmaphorum
FEBRUARY 8, 2024
China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.
STAT
FEBRUARY 8, 2024
By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies. Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023.
Drug Store News
FEBRUARY 8, 2024
One in five adults are unaware of the possibility of being sunburnt during the winter months, according to a new study by the American Academy of Dermatology.
pharmaphorum
FEBRUARY 8, 2024
Astellas appoints Nick Eshkenazi as chief digital and transformation officer (CTDO), the first time the pharma has included a digital role in its top management team
STAT
FEBRUARY 8, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. A road test for fresh pharma CEOs A lot can change in five years — including the leadership of the three major pharmaceutical companies that will be testifying before Sen.
pharmaphorum
FEBRUARY 8, 2024
BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies
STAT
FEBRUARY 8, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.
Drug Store News
FEBRUARY 8, 2024
The webinar highlighted how you can transform your pharmacy into a higher performing business that improves patient health and generates more revenue.
Drug Topics
FEBRUARY 8, 2024
June 7, 2024 is the target PDUFA date for the additional indication of GSK's respiratory syncytial virus vaccine Arexvy.
Fierce Pharma
FEBRUARY 8, 2024
After reaching a settlement with Minnesota’s attorney general, Eli Lilly can close the book on a yearslong lawsuit in the state. | The company will provide its insulin products at $35 per month and donate free insulin at 15 clinics over the next five years. Meanwhile, Minnesota's claims against Novo Nordisk and Sanofi remain ongoing.
The Checkup by Singlecare
FEBRUARY 8, 2024
Drug interactions | Food interactions | Other interactions | Avoiding interactions | When to see a doctor Mounjaro (tirzepatide) is gaining popularity as a treatment for Type 2 diabetes mellitus and off-label for weight management. In fact, in late 2023, its manufacturer, Eli Lilly, released another brand form of tirzepatide, Zepbound , with Food and Drug Administration (FDA) approval for weight loss.
Drug Store News
FEBRUARY 8, 2024
The company touts the line as representing the latest scientific advances in healthy aging, with a proven commitment to purity, efficacy and sustainability.
Expert insights. Personalized for you.
145 
Let's personalize your content